LB-100

DB15412InvestigationalSmall molecule

LB-100 is under investigation in clinical trial NCT03886662 (A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)).

Mechanism: Pharmacologically active on Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform, Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform, and Serine/threonine-protein phosphatase 5
Curator reviewed
Formula / weight: C₁₃H₂₀N₂O₄ · 268.313 g/mol (avg)
Code names: LB-100

Resolves to

Compound

UNII0C1JUU9S0LCAS1632032-53-1

Structure

InChIKeyJUQMLSGOTNKJKI-IZUQBHJASA-NSMILESCN1CCN(CC1)C(=O)C1[C@@H]2CC[C@@H](O2)C1C(O)=O

Targets

P62714PPP2CBP67775PPP2CAP53041PPP5C

What you can answer from here — as of June 15, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

8Clinical trialsPhase, status and sponsor resolved per trial

13+ReferencesStructured and connected to the statements they support

Which drugs share a target with LB-100, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account